Advances in Cancer Immunotherapy™ Regional Education Programs

The Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CE- and MOC-accredited programs presented by local authorities in tumor immunology and cancer immunotherapy and are free for healthcare professionals, students and patient advocates.

Join SITC for four hours and 30 minutes of cancer immunotherapy education, with more time devoted to each topic than ever before. This year's sessions include the following topics:

• An introduction to Cancer Immunotherapy - Learn about the basic principles behind cancer immunotherapy
• Immunotherapy in Practice - Attend sessions on lung cancer, melanoma, head and neck cancers, genitourinary cancers and hematologic malignancies
• Barriers in Practice - Recognize barriers to cancer immunotherapy
• The Future of Cancer Immunotherapy - Understand important trends, new developments, potential approvals and disease states with promising data

The new format focuses on interaction, creating an engaging learning environment.

Click any of the following links to learn more about these upcoming ACI regional education programs:

• Treat patients with lung cancer, melanoma, head and neck cancers, hematologic malignancies and genitourinary cancers with FDA-approved immunotherapies
• Interpret the most recent clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
• Identify and manage immune-related adverse events
• Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
• Apply foundational knowledge for optimized clinical implementation of SITC’s Cancer Immunotherapy Guidelines

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the event at (414) 271-2456.

The 2018–2019 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2018–2019 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. (as of Aug. 21, 2018).